Loading...
NPI 1962168369 · Lenexa, KS · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Eurofins Transplant Genomics, LLC is a clinical medical laboratory provider located in Lenexa, Kansas. This profile covers 2 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Eurofins Transplant Genomics, LLC |
| Address | 18000 W 99th St Ste 100 |
| City | Lenexa |
| State | KS |
| ZIP | 66219 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | November 10, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $20.9M |
| Medicaid | $482.9K |
EUROFINS TRANSPLANT GENOMICS, LLC’s billings are dominated by molecular pathology and a proprietary transplant dd–cfDNA assay: the Medicare top codes are 81479 and 0118U and the precomputed top-3 Medicare codes by revenue account for 100.0% of this provider's total Medicare revenue, indicating the operation is focused on high-value molecular testing rather than broad diagnostic panels. The 0118U entry is explicitly the Viracor TRAC™ dd–cfDNA assay (NGS-based transplant monitoring), which together with nonspecific molecular pathology coding (81479) defines the service line.
Revenue concentration is extreme across both payers: for Medicare, 81479 accounts for 63.9% of Medicare revenue and 0118U accounts for 36.1%, and for Medicaid 81479 accounts for 55.5% while 0118U accounts for 44.5%. The precomputed top-3 Medicaid codes by revenue account for 100.0% of this provider's total Medicaid revenue, so virtually all payer receipts flow through this very narrow code mix.
The provider is effectively Medicare-centric in scale: reported total Medicare revenue is $20.9M versus total Medicaid revenue of $482.9K, so Medicare is by far the dominant payer in dollar terms. This differential indicates the business primarily serves Medicare-covered transplant monitoring use cases, with Medicaid representing a small share of volume and revenue.
Competitive standing for the non‑specific molecular pathology code 81479 shows notable national placement: the provider’s Medicare 81479 billing ranks #8 of 80 providers nationally (91th percentile; typical, unremarkable volume for this code), and the Medicaid 81479 billing ranks #1 of 2 providers in-state (100th percentile; typical, unremarkable volume for this code). These ranks suggest the lab is a meaningful reporter of 81479 at both national (Medicare) and state (Medicaid) levels, but the underlying characterization labels the volumes as typical rather than statistical outliers.
The proprietary PLA code 0118U positions the provider as the sole reporter for that assay in available datasets: Medicare 0118U ranks #1 of 1 providers nationally (0th percentile; no national peer volume comparison available) and Medicaid 0118U ranks #1 of 1 providers in-state (0th percentile; no state peer volume comparison available). Being the only reporter of 0118U in these peer sets indicates a unique market position for this specific transplant dd–cfDNA test, but it also limits standard peer benchmarking.
Tenure is short relative to cumulative billing: the NPI was enumerated on 2021-11-10 (~5 years ago), and in that period the entity has generated $20.9M in Medicare revenue and $482.9K in Medicaid revenue. This suggests rapid revenue accumulation for a lab focused on specialized transplant monitoring assays within a relatively short operational window.
From a risk and strategy perspective, the heavy reliance on two codes (81479 and the proprietary 0118U) creates both a strategic specialization and concentration risk: the two codes together account for 100.0% of Medicare revenue and 100.0% of Medicaid revenue per the precomputed top‑3 shares, meaning payer exposure is tightly linked to continued reimbursement and demand for these specific molecular and PLA tests. For payers and network strategists, this profile signals a targeted vendor relationship centered on transplant dd–cfDNA services rather than a broad clinical lab partnership.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 4,810 | $2,770 | $13.3M |
| 0118U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0118U for the… | 2,810 | $2,680 | $7.5M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 2 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 1,530 | $180 | $267.6K |
| 0118U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0118U for the… | 1,110 | $190 | $215K |
How this provider's Medicaid billing volume and revenue compare to other Kansas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Kansas median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 0118U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0118U for the… | 1 | 10 | 1,110 | $190 | $215.4K |
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 1 | 10 | 800 | $170 | $133.8K |
Other providers in the same ZIP code as Eurofins Transplant Genomics, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.